Excited to share our latest from @UCCancerCenter -
Response to Treatment, Racial and Ethnic Disparity, and Survival in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy in the US
@fredhow@folopade@UChicagoBreast
https://t.co/c7didsfFxo
We trained models to account for biases in TCGA https://t.co/H4W8iH23lA https://t.co/0BwkztJW8R - resulting in equal accuracy in training / validation in our diverse @UChicagoMed cohort. We also saw equal accuracy in Black patients - important for #healthequity in #technology
In an analysis of over one million pts with #breastcancer, HER2-low status had minimal impact on breast cancer survival & chemotherapy response when compared to HER2-0 disease in an analysis prior to introduction of potent antibody-drug conjugates. https://t.co/Z4T9r6MzBU #BCSM